Moreover, osimertinib monotherapy may also be used in patients with rare mutations in exons 18–21 of the EGFR gene (except patients with insertions in exon 20) and in patients with locally advanced NSCLC without the possibility of radical treatment [12]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.